Radulovacki M, Wojcik W J, Fornal C, Miletich R
Pharmacol Biochem Behav. 1980 Jul;13(1):51-5. doi: 10.1016/0091-3057(80)90120-3.
Two alpha-adrenoreceptor blocking agents, phentolamine (5 mg/kg, IP) and phenoxybenzamine (10 mg/kg IP) were administered to rats deprived of rapid eye movement (REM) sleep for 24 hours to test the hypothesis that reduced noradrenergic transmission may abolish REM sleep rebound. The hypothesis was based on results from our previous studies which showed that administration to rats of diethyldithiocarbamate (DDC), a dopamine beta hydroxylase inhibitor, decreased the concentration of brain norepinephrine and reduced REM sleep permanently without the subsequent appearance of REM sleep rebound. Present results show that administration of both alpha-adrenoreceptor blockers abolished REM sleep rebound. At the time of maximum reduction of REM sleep, the concentration of 3-methoxy-4-hydroxyphenylethyleneglycol sulfate (MOPEGSO4), a final product of norepinephrine metabolism in the brain, was found increased in the whole brains of rats suggesting that the selected doses of the drugs were sufficient to produce effective central alpha-adrenergic receptor blockade. These data indicate that the action of both alpha-adrenoreceptor blocking agents in noradrenergic system was paralleled by the permanent loss of REM sleep and support the hypothesis implicating reduced noradrenergic transmission in elimination of REM sleep rebound.
给快速眼动（REM）睡眠被剥夺24小时的大鼠注射两种α-肾上腺素能受体阻断剂，酚妥拉明（5毫克/千克，腹腔注射）和酚苄明（10毫克/千克，腹腔注射），以检验去甲肾上腺素能传递减少可能消除REM睡眠反跳这一假说。该假说基于我们之前的研究结果，即给大鼠注射多巴胺β羟化酶抑制剂二乙基二硫代氨基甲酸盐（DDC）会降低脑内去甲肾上腺素浓度，并永久性减少REM睡眠且随后不会出现REM睡眠反跳。目前的结果表明，两种α-肾上腺素能受体阻断剂的给药均消除了REM睡眠反跳。在REM睡眠最大程度减少时，发现脑内去甲肾上腺素代谢终产物3-甲氧基-4-羟基苯乙二醇硫酸盐（MOPEGSO4）的浓度在大鼠全脑中升高，这表明所选药物剂量足以产生有效的中枢α-肾上腺素能受体阻断作用。这些数据表明，两种α-肾上腺素能受体阻断剂在去甲肾上腺素能系统中的作用与REM睡眠的永久性丧失相平行，并支持了在消除REM睡眠反跳中涉及去甲肾上腺素能传递减少的假说。
